Testing a CD33-targeted drug for difficult AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old, and expected to live at least 3 months
- Your AML must be CD33-positive and confirmed by blood or bone marrow tests
- Your bone marrow should have at least 5% blasts (immature AML cells)
- Your overall strength should be limited but not too severe (ECOG 0 to 2)
- Your white blood cell count before the first dose must be 25 or lower
- You must have recovered from prior treatment side effects to mild level (no more than Grade 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (RJK-RT2831) for people with AML that has not responded to standard treatments. The drug targets two markers on leukemia cells (CD33 and CD123). The study is early-stage, aiming to find the right dose and check safety.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This trial tests an experimental drug called BL-M11D1 for people with myelodysplastic syndromes (MDS) that has come back or not improved with standard treatment. The drug targets a protein called CD33 on cancer cells and may help reduce the number of abnormal cells in the bone marrow.
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.